DefEYE Inc., previously a subsidiary of Verséa Health operating as Verséa Ophthalmics, announced its launch as an independent company, according to a press release.
DefEYE launched with a portfolio of decellularized biologics, including Biovance 3L Ocular and Biovance amniotic decellularized basement membrane products, which are designed to help manage the ocular surface by protecting and preserving tissue.
“The optimization of the ocular surface is crucial to both managing patient symptoms and signs as well as to support consistent surgical outcomes,” Rob Sambursky, MD, CEO of